BERGEN, Norway, May
29, 2018 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO) will host a
conference call on Monday, 4 June at 8:30 AM
CEST to present updated interim clinical and biomarker
results from its ongoing Phase II development programme with
selective AXL inhibitor bemcentinib. The data will be presented at
the Annual American Society of Clinical Oncology (ASCO) meeting and
at a reception hosted by BerGenBio (details below).
Conference call details:
The call will be hosted by BerGenBio senior management and take
place on:
Monday, 4 June 2018 at
8:30 AM CEST.
To take part, please dial in 5-10 minutes prior to the scheduled
start using below phone number and confirmation code
1068189:
Norway +47-2100-2608
United
Kingdom +44-(0)-330-336-9106
United
States +1-323-794-2594
A slide deck presentation to accompany the call will be made
available at www.bergenbio.com in the Investors /
Presentations section from 8:00 AM
CEST on 4 June 2018.
Presentations to be made during the annual ASCO
meeting:
Saturday 2 June, 6:00 – 8:00 PM
CDT, Chicago School of the Art Institute, Chicago, IL
- New interim Phase II clinical trial data with bemcentinib and
selected pre-clinical data to be discussed by BerGenBio principal
investigators and invited key opinion leaders
- For further details and to receive an invitation, please email
to asco2018@bergenbio.com
Monday 4 June, 8:00 AM - 11:30 AM
CDT, ASCO Annual Meeting, McCormick Center, Chicago, IL
- Interim clinical data from clinical trial ref. BGBC008 – Poster
Board: #292, Abstract 3078
- Interim clinical data from clinical trial ref. BGBC003 – Poster
Board: #80, Abstract 7020
- To be discussed at the Poster Discussion Session. 11:30 AM - 12:45 PM CDT
- Biomarker study – Poster Board: #385, Abstract
2559
Monday 4 June, 1:15 PM –
4:45 PM CDT, ASCO Annual Meeting,
McCormick Center, Chicago, IL
- Interim clinical data from clinical trial ref. BGBIL006 –
Poster Board: #375, Abstract 9548
The posters presented at ASCO will be made
available www.bergenbio.com in the Investors /
Presentations section at the time of presentation.
-End-
About BerGenBio ASA
BerGenBio ASA is a clinical-stage biopharmaceutical company
focused on developing a pipeline of first-in-class AXL kinase
inhibitors as a potential cornerstone of combination cancer
therapy. The Company is a world leader in understanding the
essential role of AXL kinase in mediating aggressive disease,
including immune evasive, drug resistant, metastatic solid and
haematological cancers.
BerGenBio's lead product, bemcentinib (BGB324), is a selective,
potent and orally bio-available small molecule AXL inhibitor in
four Company sponsored Phase II clinical trials in major cancer
indications, with read-outs anticipated during 2018. It is the only
selective AXL inhibitor in clinical development.
The Company sponsored clinical trials are:
- Bemcentinib with TARCEVA® (erlotinib) in advanced EGFR mutation
driven non-small cell lung cancer (NSCLC)
- Bemcentinib with KEYTRUDA in advanced adenocarcinoma of the
lung, and
- Bemcentinib with KEYTRUDA in triple-negative breast cancer
(TNBC).
- Bemcentinib as a single agent and combination therapy in acute
myeloid leukaemia (AML) / myeloid dysplastic syndrome (MDS)
The clinical trials combining bemcentinib with KEYTRUDA in
adenocarcinoma of the lung and TNBC are conducted in collaboration
with Merck & Co., Inc. (Kenilworth,
NJ, USA), through a subsidiary.
In addition, a number of investigator-sponsored trials are
underway, including a trial to investigate bemcentinib with either
MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or KEYTRUDA in
advanced melanoma, as well as a trial combining bemcentinib with
docetaxel in advanced NSCLC.
BerGenBio is simultaneously developing a companion diagnostic
test to identify patient subpopulations most likely to benefit from
treatment with bemcentinib. This will facilitate more efficient
registration trials and support a precision medicine based
commercialization strategy.
The Company is also developing a diversified pre-clinical
pipeline of drug candidates, including BGB149, an anti-AXL
monoclonal antibody.
For further information, please
visit: www.bergenbio.com
KEYTRUDA® is a registered trademark of Merck Sharp &
Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, TARCEVA® is a registered
trademark of OSI Pharmaceuticals, LLC., marketed by
Roche-Genentech. TAFLINAR® is a registered trademark of
Novartis International AG and MEKINIST® is a registered trademark
of GSK plc.
Contacts
Richard Godfrey
CEO
BerGenBio ASA
+47-917-86-304
Rune Skeie
CFO
BerGenBio ASA
rune.skeie@bergenbio.com
+47-917-86-513
Media Relations in Norway
Jan Petter Stiff
Crux Advisers
stiff@crux.no
+47-995-13-891
International Media Relations
David Dible
Mark Swallow
Marine Perrier
Citigate Dewe Rogerson
bergenbio@citigatedewerogerson.com
+44-207-638-9571
Forward looking statements
This announcement may contain forward-looking statements,
which as such are not historical facts, but are based upon various
assumptions, many of which are based, in turn, upon further
assumptions. These assumptions are inherently subject to
significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and
other important factors could cause actual events to differ
materially from the expectations expressed or implied in this
announcement by such forward-looking statements
This information is subject to the disclosure requirements
pursuant to section 5-12 of the Norwegian Securities Trading
Act.
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/bergenbio-asa/r/bergenbio---invitation-to-conference-call--interim-update-on-ph-ii-clinical-programme-with-selective,c2533435